| Emma Manning, DPT | |
|
7226 Commons Dr Ste B, Cheyenne, WY 82009-2678 | |
| (307) 514-5834 | |
| (307) 514-5837 |
| Full Name | Emma Manning |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 5 Years |
| Location | 7226 Commons Dr Ste B, Cheyenne, Wyoming |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578178802 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 1995 (Wyoming) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Platte Physical Therapy Services Inc | 8921080565 | 30 |
News Archive
Doping is damaging the image of sport without benefitting athletes' results, according to University of Adelaide research.
Gonadotropin-releasing hormone analogue given alongside growth hormone during puberty in order to increase adult height does not have long-term metabolic health consequences in children born small for gestational age, research shows.
Tenofovir gel, a vaginal microbicide that has shown promise for preventing HIV through vaginal sex, is being tested in a new trial looking at its safety and acceptability when used rectally. The results of the study, being led by the U.S. National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN), will help determine if the gel should be evaluated further for its potential to prevent HIV among both men and women who engage in receptive anal intercourse.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.
› Verified 1 days ago
| Provider Name | North Platte Physical Therapy Services Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1093914111 PECOS PAC ID: 8921080565 Enrollment ID: O20040607000307 |
News Archive
Doping is damaging the image of sport without benefitting athletes' results, according to University of Adelaide research.
Gonadotropin-releasing hormone analogue given alongside growth hormone during puberty in order to increase adult height does not have long-term metabolic health consequences in children born small for gestational age, research shows.
Tenofovir gel, a vaginal microbicide that has shown promise for preventing HIV through vaginal sex, is being tested in a new trial looking at its safety and acceptability when used rectally. The results of the study, being led by the U.S. National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN), will help determine if the gel should be evaluated further for its potential to prevent HIV among both men and women who engage in receptive anal intercourse.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.
› Verified 1 days ago
| Provider Name | Big Country Rehabilitation Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1366493264 PECOS PAC ID: 0648253666 Enrollment ID: O20040610001233 |
News Archive
Doping is damaging the image of sport without benefitting athletes' results, according to University of Adelaide research.
Gonadotropin-releasing hormone analogue given alongside growth hormone during puberty in order to increase adult height does not have long-term metabolic health consequences in children born small for gestational age, research shows.
Tenofovir gel, a vaginal microbicide that has shown promise for preventing HIV through vaginal sex, is being tested in a new trial looking at its safety and acceptability when used rectally. The results of the study, being led by the U.S. National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN), will help determine if the gel should be evaluated further for its potential to prevent HIV among both men and women who engage in receptive anal intercourse.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.
› Verified 1 days ago
| Provider Name | Bear Lodge Rehabilitation Services, Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1558690099 PECOS PAC ID: 7911041199 Enrollment ID: O20100225000900 |
News Archive
Doping is damaging the image of sport without benefitting athletes' results, according to University of Adelaide research.
Gonadotropin-releasing hormone analogue given alongside growth hormone during puberty in order to increase adult height does not have long-term metabolic health consequences in children born small for gestational age, research shows.
Tenofovir gel, a vaginal microbicide that has shown promise for preventing HIV through vaginal sex, is being tested in a new trial looking at its safety and acceptability when used rectally. The results of the study, being led by the U.S. National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN), will help determine if the gel should be evaluated further for its potential to prevent HIV among both men and women who engage in receptive anal intercourse.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Emma Manning, DPT Po Box 1790, Douglas, WY 82633-1790 Ph: (307) 358-9464 | Emma Manning, DPT 7226 Commons Dr Ste B, Cheyenne, WY 82009-2678 Ph: (307) 514-5834 |
News Archive
Doping is damaging the image of sport without benefitting athletes' results, according to University of Adelaide research.
Gonadotropin-releasing hormone analogue given alongside growth hormone during puberty in order to increase adult height does not have long-term metabolic health consequences in children born small for gestational age, research shows.
Tenofovir gel, a vaginal microbicide that has shown promise for preventing HIV through vaginal sex, is being tested in a new trial looking at its safety and acceptability when used rectally. The results of the study, being led by the U.S. National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN), will help determine if the gel should be evaluated further for its potential to prevent HIV among both men and women who engage in receptive anal intercourse.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.
› Verified 1 days ago
Bluegrass Physical Therapy Limited Partnership Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1950 Bluegrass Cir, Suite 110, Cheyenne, WY 82009 Phone: 307-634-2626 Fax: 307-634-5099 | |
Mrs. Linda Rc Froelicher, MSPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 4000 Central Ave, Suite #3, Cheyenne, WY 82001 Phone: 307-634-0298 Fax: 307-634-0837 | |
Nicholas Robert Johnson, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1900 Converse Ave Ste B, Cheyenne, WY 82001 Phone: 307-514-2411 Fax: 307-514-2392 | |
Byron Louis Long, MPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1950 Bluegrass Cir, Suite 110, Cheyenne, WY 82009 Phone: 307-634-2626 Fax: 307-634-5099 | |
Mr. Thomas James Bledsoe, M.P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 4017 Rawlins St, Cheyenne, WY 82001 Phone: 307-635-2562 | |
Sandra Champlin, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1951 Bluegrass Cir, Cheyenne, WY 82009 Phone: 307-773-8533 Fax: 307-635-7578 | |
Dr. Charlene Marie Sheamansmith, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 4515 E Pershing Blvd Unit C, Cheyenne, WY 82001 Phone: 307-635-2388 Fax: 307-635-1730 |